1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 0,139 | 0,197 | 19:02 |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| Fr | Cantargia Announces Changes in Number of Shares and Votes | 259 | ACCESS Newswire | LUND, SE / ACCESS Newswire / July 31, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that the number of shares and votes in Cantargia has changed due to the recently... ► Artikel lesen | |
| 26.06. | Cantargia Announces Publication of Data Supporting IL1RAP as a Therapeutic Target and Predictive Biomarker in PDAC | 315 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 26, 2026 / Cantargia AB (publ) (STO:CANTA) today announced the publication of preclinical and clinical findings from the nadunolimab trial CANFOUR in the scientific... ► Artikel lesen | |
| 23.06. | Cantargia AB: Cantargia announces outcome in rights issue and resolves on a directed issue of warrants to Fenja Capital | 183 | GlobeNewswire (Europe) | NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES, AUSTRALIA, BELARUS, HONG KONG, JAPAN, CANADA, NEW ZEALAND, RUSSIA, SINGAPORE... ► Artikel lesen | |
| 11.06. | Cantargia and H.C. Wainwright to Host KOL Call on The Case for Nadunolimab in PDAC | 251 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 11, 2026 / Cantargia AB (Publ) (STO:CANTA) today announced a KOL Call to be hosted in collaboration with H.C. Wainwright with leading subject matter experts Drs. Peter... ► Artikel lesen | |
| 10.06. | Cantargia Announces Start of New Investigator-Initiated Lung Cancer Prevention Study | 335 | ACCESS Newswire | LUND, SE / ACCESS Newswire / June 10, 2026 / Cantargia AB (Publ) (STO:CANTA) today reported that the first patient has been dosed in a Phase 2 clinical trial investigating nadunolimab in up to 59 current... ► Artikel lesen | |
| CANTARGIA Aktie jetzt für 0€ handeln | |||||
| 05.06. | Cantargia AB: Cantargia publishes Information Document regarding Rights Issue of Shares | 251 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") publishes an information document (the "Information Document") relating to the rights issue of shares of approximately SEK 124 million before deduction... ► Artikel lesen | |
| 03.06. | XFRA CAPITAL ADJUSTMENT INFORMATION - 03.06.2026 | 422 | Xetra Newsboard | Das Instrument 7V3 SE0006371126 CANTARGIA AB EQUITY wird ex Kapitalmassnahme gehandelt am 03.06.2026 The instrument 7V3 SE0006371126 CANTARGIA AB EQUITY is traded ex capital adjustment on 03.06.2026Das... ► Artikel lesen | |
| 28.05. | Cantargia AB to Host Webcast Covering Rights Issue, Loan Agreement, and Strategic Priorities | 376 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 28, 2026 / Cantargia (STO:CANTA) - With reference to the Company's press release on May 28, 2026, regarding the decision to conduct a rights issue in combination with... ► Artikel lesen | |
| 28.05. | Cantargia AB: Cantargia AB carries out a rights issue of SEK 124 million and enters into a loan agreement of up to SEK 75 million | 527 | GlobeNewswire (Europe) | Cantargia AB (publ) ("Cantargia" or the "Company") hereby announces that the board of directors has resolved to carry out a new share issue of approximately SEK 124 million with preferential rights... ► Artikel lesen | |
| 21.05. | Bulletin from the Annual General Meeting in Cantargia AB | 366 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 21, 2026 / Cantargia (STO:CANTA) - The Annual General Meeting of Cantargia AB (publ) on May 21, 2026 resolved in accordance with the following:To adopt the income statement... ► Artikel lesen | |
| 19.05. | Cantargia Publishes Interim Report for The First Quarter of 2026 | 410 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 19, 2026 / Cantargia AB (publ); Nasdaq Stockholm:CANTA) today announced its interim report for the first quarter of 2026."The first quarter of 2026 reflects both strong... ► Artikel lesen | |
| 06.05. | Invitation to the Presentation of Cantargia's Interim Report for Q1 2026 | 336 | ACCESS Newswire | LUND, SE / ACCESS Newswire / May 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's interim report for Q1 2026 on Tuesday, May 19, 2026, at 07:00 a.m. CEST.In conjunction... ► Artikel lesen | |
| 27.04. | Cantargia Announces Early Results from Trial of Nadunolimab in MDS and AML | 395 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 27, 2026 / Cantargia AB (Nasdaq Stockholm:CANTA), a clinical-stage biotechnology company focused on antibody-based therapeutics targeting IL1RAP, today announced early... ► Artikel lesen | |
| 17.04. | Cantargia Announces AACR 2026 Presentation of Study Design and Supportive Pre-Clinical Data for Investigator-Initiated Nadunolimab Study in MSS CRC | 472 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - Cantargia AB (Publ) (Nasdaq Stockholm:CANTA) today reported that the rationale and study design of the phase 1b/2 clinical trial... ► Artikel lesen | |
| 17.04. | Notice of Annual General Meeting in Cantargia AB | 265 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia (STO:CANTA) - The shareholders of Cantargia AB (publ), reg. no. 556791-6019, are invited to the annual general meeting on Thursday, 21 May 2026... ► Artikel lesen | |
| 17.04. | Cantargia Publishes Annual Report 2025 | 278 | ACCESS Newswire | LUND, SE / ACCESS Newswire / April 17, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) today announced that the annual report for 2025 has been published. The Annual Report is attached to this press... ► Artikel lesen | |
| 05.03. | Cantargia to Participate at Van Lanschot Kempen's Life Sciences Conference | 807 | ACCESS Newswire | LUND, SE / ACCESS Newswire / March 5, 2026 / Cantargia AB (publ) ("Cantargia") (Nasdaq Stockholm:CANTA) today announced that members of Cantargias management will participate in one-on-one meetings... ► Artikel lesen | |
| 23.02. | Cantargia to Participate in TD Cowen's Annual Healthcare Conference | 451 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 23, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA)(STO:CANTA) today announced that members of Cantargia's management will participate in and host 1-1 meetings... ► Artikel lesen | |
| 20.02. | Cantargia Publishes Full Year Report 2025 | 360 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 20, 2026 / Cantargia AB's (publ) ("Cantargia") (Nasdaq Stockholm:CANTA)(STO:CANTA) full year report for 2025 is now available on the company's web page www.cantargia.com/en/investors/financial-reports."Cantargia... ► Artikel lesen | |
| 06.02. | Invitation to the Presentation of Cantargia's Annual Results for 2025 | 381 | ACCESS Newswire | LUND, SE / ACCESS Newswire / February 6, 2026 / Cantargia AB (publ) (Nasdaq Stockholm:CANTA) will publish the company's annual results report for 2025 on Friday, February 20, 2026, at 07:00 a.m. CET.In... ► Artikel lesen |
1 2 Weiter >>
34 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| BIONTECH | 79,05 | -1,37 % | Neue Folge "Börse, Baby!": Earnings-Alarm: Jetzt entscheidet sich der KI-Boom | Die KI-Euphorie bekommt erste Risse: Trotz starker Quartalszahlen geraten Tech-Aktien kräftig unter Druck. Ist das noch eine gesunde Korrektur? Die Berichtssaison zeigt derzeit, wie hoch die Erwartungen... ► Artikel lesen | |
| EVOTEC | 3,410 | -1,22 % | Wirkstoffe, Zukäufe, Aufspaltungen: Werden Bayer, Novo Nordisk, BioNxt oder Evotec zu Top-Übernahme-Kandidaten? | Nach einer jahrelangen Konsolidierung fragen sich Investoren: Geht es auch mal wieder aufwärts? Der globale LifeScience-Sektor steht auch im Jahr 2026 vor einer massiven Konsolidierungswelle, da etablierte... ► Artikel lesen | |
| QIAGEN | 35,720 | -0,75 % | PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG | DJ PTA-PVR: QIAGEN N.V.: Veröffentlichung nach § 40 Abs. 1 WpHG
Veröffentlichung gem. -- 40 Abs. 1 WpHG
QIAGEN N.V.: Veröffentlichung nach -- 40 Abs. 1 WpHG
Venlo (pta000/29.07.2026/22:05... ► Artikel lesen | |
| REGENERON PHARMACEUTICALS | 659,60 | -0,30 % | Regeneron Pharmaceuticals Inc Bottom Line Retreats In Q2 | WASHINGTON (dpa-AFX) - Regeneron Pharmaceuticals Inc (REGN) revealed a profit for second quarter that Drops, from the same period last yearThe company's earnings totaled $1.296 billion, or $12.23... ► Artikel lesen | |
| BRAIN BIOTECH | 2,810 | -1,75 % | EQS-Adhoc: BRAIN Biotech AG: BRAIN Biotech bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden des Vorstands | EQS-Ad-hoc: BRAIN Biotech AG / Schlagwort(e): Personalentscheidungen / Vorstand
BRAIN Biotech AG bestellt Dr. Sven K. Weber zum 01. Oktober 2026 als neuen Vorsitzenden... ► Artikel lesen | |
| SCORPIUS | - | - | Antares Global launches Scorpius MGA platform under Ian Morris | ||
| CARDIOL THERAPEUTICS | 1,022 | -6,92 % | Original-Research: Cardiol Therapeutics Inc (von First Berlin Equity Research GmbH): Buy | Original-Research: Cardiol Therapeutics Inc - from First Berlin Equity Research GmbH
20.07.2026 / 16:41 CET/CEST
Dissemination of a Research, transmitted by EQS News - a service of EQS Group.
The... ► Artikel lesen | |
| CSL | 76,71 | +0,16 % | Buy, hold, sell: What is Bell Potter saying about CSL shares? | ||
| BURCON NUTRASCIENCE | 1,190 | +4,39 % | Stonegate, Inc.: Stonegate Updates Coverage on Burcon Nutrascience Corporation (BU) 4Q26 | Dallas, Texas--(Newsfile Corp. - June 26, 2026) - Burcon Nutrascience Corporation (TSX: BU): Stonegate Capital Partners updates their coverage on Burcon Nutrascience Corporation (TSX: BU). Burcon... ► Artikel lesen | |
| MANNKIND | 3,377 | 0,00 % | MannKind Reports Positive Phase 1b INFLO-1 Results, Demonstrating Safety and Tolerability of Nintedanib DPI and Clinical Validation of Its DPI Technology in IPF | Generally well-tolerated with no serious adverse events, bronchospasm or diarrhea; no study drug discontinuations 90% of patients had no [60%] or mild [30%] cough~450 total inhalations administered... ► Artikel lesen | |
| OCULAR THERAPEUTIX | 7,150 | +0,70 % | Ocular Therapeutix, Inc.: Ocular Therapeutix Announces Additional Positive Week 52 Data from Landmark SOL-1 Phase 3 Trial of AXPAXLI in Wet AMD | New SOL-1 post-hoc analyses presented at VBS reinforce AXPAXLI's unmatched durability in wet AMD with sustained disease control AXPAXLI demonstrated robust CSFT control with a median time of 39 weeks... ► Artikel lesen | |
| OXFORD NANOPORE TECHNOLOGIES | 1,352 | +1,12 % | Volta Labs launches automated library preparation solution for the Oxford Nanopore Ligation Sequencing Kit V14 | BOSTON, May 21, 2026 /PRNewswire/ -- Volta Labs, maker of the Callisto Sample Prep System, today announced the availability of its DNA Library Preparation Application for the Oxford Nanopore... ► Artikel lesen | |
| ADAPTIMMUNE THERAPEUTICS | 0,162 | 0,00 % | Merck And ADAP Crisis Task Force Reach Agreement To Expand IDVYNSO Access | ||
| CODEXIS | 1,202 | 0,00 % | Codexis, Inc.: Codexis to Report Second Quarter 2026 Financial Results on August 11 | ||
| CORMEDIX | 6,186 | -5,21 % | CorMedix, Inc.: CorMedix Therapeutics to Report Second Quarter 2026 Financial Results and Provide a Corporate Update on August 13, 2026 |
Das Unternehmen CANTARGIA AB kann der Branche Biotechnologie zugeordnet werden. Mit einer aktuellen Kursveränderung von -0,002 (-1,46 %) liegt der Kurs bei 0,135 Euro.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu CANTARGIA AB finden Sie auf Wallstreet Online.